An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. (2nd August 2020)

• Record Type: Journal Article
• Authors: Calderone, Dario; Capodanno, Davide; Angiolillo, Dominick J.
• Is Part Of: Expert review of cardiovascular therapy. Volume 18:Number 8(2020)
• Page Start: 449
• Page End: 464
• Publication Date: 2020-08-02
• Subjects: Antiplatelet -- coronary artery disease -- diabetes mellitus -- dual antiplatelet therapy -- P2Y12 inhibitor -- pharmacokinetics -- pharmacodynamic -- platelets; Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1080/14779072.2020.1792293
• Languages: English
• ISSNs: 1477-9072

Abstract

ABSTRACT: Introduction: Ticagrelor is an antiplatelet agent acting through direct and reversible competitive inhibition of the platelet P2Y12 receptor. While the clinical merits of ticagrelor in patients who experienced an acute coronary syndrome are widely accepted, its role in stable coronary artery disease is less established. Recently, large-scale trials of ticagrelor have been published in this setting, including a trial in patients with diabetes mellitus (DM). Areas covered: This review aims to inform about recent findings on ticagrelor, by appraising the current body of evidence on its use in different clinical scenarios, particularly in DM, ranging from pharmacology to clinical outcomes and future directions. Expert opinion: The results of the THEMIS trial, conducted in DM patients with stable coronary artery disease and no prior stroke or myocardial infarction, showed that although ticagrelor in addition to aspirin reduced the risk of ischemic events, this was associated with a parallel increase in bleeding complications. However, patients with history of percutaneous coronary intervention seemed to benefit more from adjunctive ticagrelor therapy. Careful bleeding and ischemic risk stratification remains crucial to define the best antithrombotic strategy for the individual patient.